Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: A meta-analysis

Bipolar Disorders

Volumn 14, Issue 5, 2012, Pages 478-487

  Gigante, Alexandre Duarte ^a,b   Bond, David J ^a   Lafer, Beny ^a,b   Lam, Raymond W ^a   Young, L Trevor ^c   Yatham, Lakshmi N ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bipolar disorder; Glutamate; Glutamate+glutamine (Glx); Meta analysis; Proton magnetic resonance spectroscopy

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; CREATINE; GLUTAMIC ACID; GLUTAMINE; LAMOTRIGINE; LITHIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; VALPROIC ACID;

AMINO ACID BRAIN LEVEL; ANTERIOR CINGULATE; BASAL GANGLION; BIPOLAR DISORDER; BRAIN METABOLISM; EXCITOTOXICITY; FRONTAL LOBE; GLUTAMATE BRAIN LEVEL; HIPPOCAMPUS; HUMAN; MEDLINE; MENTAL PATIENT; META ANALYSIS; OCCIPITAL CORTEX; ORBITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SYSTEMATIC REVIEW; TEMPORAL LOBE; WHITE MATTER;

ADOLESCENT; ADULT; BIPOLAR DISORDER; BRAIN; CHILD; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84864388823     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2012.01033.x     Document Type: Review

References (73)

1. Merikangas K, Akiskal H, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552.
2. Tohen M, Hennen J, Zarate CJ et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000; 157: 220-228.
3. MacQueen G, Young L, Joffe R. A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatr Scand 2001; 103: 163-170.
4. Rosa A, Reinares M, Michalak E et al. Functional impairment and disability across mood states in bipolar disorder. Value Health 2010; 13: 984-988.
5. Torres I, DeFreitas V, DeFreitas C et al. Neurocognitive functioning in patients with bipolar I disorder recently recovered from a first manic episode. J Clin Psychiatry 2010; 71: 1234-1242.
6. Murray C, Lopez A. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996; 274: 740-743.
7. Kato T. Molecular neurobiology of bipolar disorder: a disease of 'mood-stabilizing neurons'? Trends Neurosci 2008; 31: 495-503.
8. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. New York: Oxford University Press, 2007.
9. Martinowich K, Schloesser R, Manji H. Bipolar disorder: from genes to behavior pathways. J Clin Invest 2009; 119: 726-736.
10. Arnone D, Cavanagh J, Gerber D, Lawrie S, Ebmeier K, McIntosh A. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. Br J Psychiatry 2009; 195: 194-201.
11. Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord 2002; 4: 105-116.
12. Gigante AD, Young LT, Yatham LN et al. Morphometric postmortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. Int J Neuropsychopharmacol 2010; 23: 1-15.
13. Wang J, Shao L, Sun X, Young L. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009; 11: 523-529.
14. Andreazza A, Kauer-Sant'anna M, Frey B et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008; 111: 135-144.
15. Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2000; 2: 180-190.
16. Schloesser R, Huang J, Klein P, Manji H. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008; 33: 110-133.
17. Kapczinski F, Frey B, Kauer-Sant'Anna M, Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother 2008; 8: 1101-1113.
18. Zarate CJ, Singh J, Manji H. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006; 59: 1006-1020.
19. Hassel B, Dingledine R. Glutamate. In: Siegel GJ, Albers RW, Brady ST, Price DL eds. Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. San Diego: Academic Press, 2006: 267-290.
20. Altamura C, Mauri M, Ferrara A, Moro A, D'Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993; 150: 1731-1733.
21. Hoekstra R, Fekkes D, Loonen A, Pepplinkhuizen L, Tuinier S, Verhoeven W. Bipolar mania and plasma amino acids: increased levels of glycine. Eur Neuropsychopharmacol 2006; 16: 71-77.
22. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007; 62: 1310-1316.
23. Kristiansen L, Meador-Woodruff J. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res 2005; 78: 87-93.
24. Beneyto M, Meador-Woodruff J. Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia. Synapse 2006; 60: 585-598.
25. McCullumsmith R, Kristiansen L, Beneyto M, Scarr E, Dean B, Meador-Woodruff J. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 2007; 1127: 108-118.
26. Mundo E, Tharmalingham S, Neves-Pereira M et al. Evidence that the N-methyl-d-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol Psychiatry 2003; 8: 241-245.
27. Itokawa M, Yamada K, Iwayama-Shigeno Y, Ishitsuka Y, Detera-Wadleigh S, Yoshikawa T. Genetic analysis of a functional GRIN2A promoter (GT)n repeat in bipolar disorder pedigrees in humans. Neurosci Lett 2003; 345: 53-56.
28. Sanacora G, Zarate C, Krystal J, Manji H. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008; 7: 426-437.
29. Michael N, Erfurth A, Ohrmann P et al. Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology 2003; 168: 344-346.
30. Dager S, Friedman S, Parow A et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 2004; 61: 450-458.
31. Frye M, Watzl J, Banakar S et al. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology 2007; 32: 2490-2499.
32. Bhagwagar Z, Wylezinska M, Jezzard P et al. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 2007; 61: 806-812.
33. Colla M, Schubert F, Bubner M et al. Glutamate as a spectroscopic marker of hippocampal structural plasticity is elevated in long-term euthymic bipolar patients on chronic lithium therapy and correlates inversely with diurnal cortisol. Mol Psychiatry 2009; 14: 696-704.
34. Davanzo P, Yue K, Thomas M et al. Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents. Am J Psychiatry 2003; 160: 1442-1452.
35. Frey B, Stanley J, Nery F et al. Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo 1H MRS study. Bipolar Disord 2007; 9 (Suppl. 1): 119-127.
36. Olvera R, Caetano S, Fonseca M et al. Low levels of N-acetyl aspartate in the left dorsolateral prefrontal cortex of pediatric bipolar patients. J Child Adolesc Psychopharmacol 2007; 17: 461-473.
37. Kaufman R, Ostacher M, Marks E et al. Brain GABA levels in patients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 427-434.
38. Singh M, Spielman D, Adleman N et al. Brain glutamatergic characteristics of pediatric offspring of parents with bipolar disorder. Psychiatry Res 2010; 182: 165-171.
39. DelBello M, Cecil K, Adler C, Daniels J, Strakowski S. Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2006; 31: 1264-1273.
40. Michael N, Erfurth A, Pfleiderer B. Elevated metabolites within dorsolateral prefrontal cortex in rapid cycling bipolar disorder. Psychiatry Res 2009; 172: 78-81.
41. Gruetter R, Novotny E, Boulware S et al. Localized 13C NMR spectroscopy in the human brain of amino acid labeling from d-[1-13C]glucose. J Neurochem 1994; 63: 1377-1385.
42. Heath P, Shaw P. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002; 26: 438-458.
43. Castillo M, Kwock L, Courvoisie H, Hooper S. Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. AJNR Am J Neuroradiol 2000; 21: 832-838.
44. Barker P, Hearshen D, Boska M. Single-voxel proton MRS of the human brain at 1.5T and 3.0T. Magn Reson Med 2001; 45: 765-769.
45. Nery F, Stanley J, Chen H et al. Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study. J Psychiatr Res 2010; 44: 278-285.
46. Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001; 265: 54-84.
47. Ongür D, Jensen JE, Prescot AP et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry 2008; 64: 718-726.
48. Dong X, Wang Y, Qin Z. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 2009; 30: 379-387.
49. Rao J, Harry G, Rapoport S, Kim H. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010; 15: 384-392.
50. Shao L, Young L, Wang J. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 2005; 58: 879-884.
51. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang D. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002; 80: 589-597.
52. Rao J, Ertley R, Rapoport S, Bazinet R, Lee H. Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2. J Neurochem 2007; 102: 1918-1927.
53. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005; 10: 900-919.
54. Clausen T, Zauner A, Levasseur JE, Rice AC, Bullock R. Induced mitochondrial failure in the feline brain: implications for understanding acute post-traumatic metabolic events. Brain Res 2001; 908: 35-48.
55. Chuang D, Chen R, Chalecka-Franaszek E et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002; 4: 129-136.
56. Atmaca M. Valproate and neuroprotective effects for bipolar disorder. Int Rev Psychiatry 2009; 21: 410-413.
57. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J Neurochem 1993; 60: 1650-1657.
58. Schubert M, Kalisch R, Sotiropoulos I et al. Effects of altered corticosteroid milieu on rat hippocampal neurochemistry and structure-an in vivo magnetic resonance spectroscopy and imaging study. J Psychiatr Res 2008; 42: 902-912.
59. Daban C, Vieta E, Mackin P, Young A. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005; 28: 469-480.
60. Kim Y, Jung H, Myint A, Kim H, Park S. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007; 104: 91-95.
61. Kapczinski F, Dal-Pizzol F, Teixeira A et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011; 45: 156-161.
62. Schmider J, Lammers C, Gotthardt U, Dettling M, Holsboer F, Heuser I. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry 1995; 38: 797-802.
63. Watson S, Gallagher P, Ritchie J, Ferrier I, Young A. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004; 184: 496-502.
64. Cousins D, Butts K, Young A. The role of dopamine in bipolar disorder. Bipolar Disord 2009; 11: 787-806.
65. Carr D, Sesack S. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 2000; 20: 3864-3873.
66. Sesack S, Carr D, Omelchenko N, Pinto A. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann N Y Acad Sci 2003; 1003: 36-52.
67. Aalto S, Ihalainen J, Hirvonen J et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology 2005; 182: 375-383.
68. Del Arco A, Mora F. Neurotransmitters and prefrontal cortex-limbic system interactions: implications for plasticity and psychiatric disorders. J Neural Transm 2009; 116: 941-952.
69. Frye M, Thomas M, Yue K et al. Reduced concentrations of N-acetylaspartate (NAA) and the NAA-creatine ratio in the basal ganglia in bipolar disorder: a study using 3-Tesla proton magnetic resonance spectroscopy. Psychiatry Res 2007; 154: 259-265.
70. Senaratne R, Milne A, MacQueen G, Hall G. Increased choline-containing compounds in the orbitofrontal cortex and hippocampus in euthymic patients with bipolar disorder: a proton magnetic resonance spectroscopy study. Psychiatry Res 2009; 172: 205-209.
71. Gonul A, Coburn K, Kula M. Cerebral blood flow, metabolic, receptor, and transporter changes in bipolar disorder: the role of PET and SPECT studies. Int Rev Psychiatry 2009; 21: 323-335.
72. Moore C, Frazier J, Glod C et al. Glutamine and glutamate levels in children and adolescents with bipolar disorder: a 4.0-T proton magnetic resonance spectroscopy study of the anterior cingulate cortex. J Am Acad Child Adolesc Psychiatry 2007; 46: 524-534.
73. Davanzo P, Thomas M, Yue K et al. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology 2001; 24: 359-369.